Trinity Biotech Advances Prostate Cancer Test with New Collaboration

Trinity Biotech (NASDAQ: TRIB) has announced a strategic collaboration designed to accelerate the development of its innovative EpiCapture prostate cancer test. The partnership with a leading bioinformatics company will apply advanced data analysis to clinical trial information, refining the test’s capabilities and moving it closer to regulatory approval and commercialization. This initiative represents a significant step forward in the company’s mission to improve non-invasive diagnostics for a disease that affects millions of men globally.

The EpiCapture test is a PCR-based liquid biopsy that analyzes epigenetic markers, specifically DNA methylation patterns, associated with the progression to high-grade prostate cancer. By offering a non-invasive method for monitoring the disease, Trinity Biotech aims to provide a critical tool for clinicians and patients, potentially reducing the need for more invasive procedures.

This collaboration is a key component of Trinity Biotech’s strategy to expand its portfolio of clinically impactful technologies. By leveraging sophisticated bioinformatics, the company intends to enhance the depth of analysis from its clinical data, thereby strengthening its submission to regulatory bodies and preparing for a successful market launch.

The Challenge of Monitoring Prostate Cancer

Prostate cancer is the most common non-skin cancer affecting men in the United States. Statistics show that approximately one in eight men will be diagnosed in their lifetime. The economic impact is substantial, with diagnosis and treatment costs estimated to exceed $10 billion annually.

A primary challenge in managing prostate cancer is its often slow-growing nature. This characteristic makes accurate and consistent monitoring essential to determine if and when the cancer becomes more aggressive. Current monitoring protocols often involve repeated invasive procedures, most notably prostate biopsies. While necessary, biopsies carry inherent risks, including infection, bleeding, and urinary complications.

The development of a reliable, non-invasive test like EpiCapture could transform this landscape. By providing an accurate assessment of progression risk without the need for a biopsy, the test has the potential to reduce unnecessary medical interventions, alleviate patient anxiety, and improve overall quality of care. This shift would not only enhance patient outcomes but also help manage the significant costs associated with current diagnostic pathways.

Clinical Validation and Market Potential

The promise of the EpiCapture test is supported by strong clinical evidence. A study published in The Journal of Clinical Oncology – Precision Oncology demonstrated the test’s high predictive accuracy. When used in conjunction with the standard Prostate-Specific Antigen (PSA) test, EpiCapture correctly identified all high-grade cancers in the study cohort.

These findings underscore the test’s potential to become an integral part of clinical decision-making. For patients with low-grade prostate cancer, a negative EpiCapture result could provide reassurance and support a decision to continue active surveillance rather than pursuing immediate, aggressive treatment. Conversely, a positive result would signal a higher risk, enabling clinicians to intervene earlier and more decisively.

As Trinity Biotech moves EpiCapture through late-stage development, it will utilize its New York State certified reference laboratory to support the final phases of testing and preparation for regulatory submission. This internal expertise in diagnostics provides a solid foundation for bringing the test from the laboratory to the clinic.

Trinity Biotech’s Vision for Diagnostic Innovation

This collaboration is part of Trinity Biotech’s broader commitment to advancing human diagnostics and diabetes management solutions. The company develops, manufactures, and markets a wide range of diagnostic systems for both point-of-care and clinical laboratory settings. With a global distribution network spanning over 75 countries, Trinity Biotech is positioned to deliver its innovations worldwide.

The company has also recently expanded into the wearable biosensor industry through the acquisition of assets from Waveform Technologies Inc. This move signals an intent to develop a new generation of health monitoring devices, starting with a continuous glucose monitoring product.

By advancing technologies like the EpiCapture test, Trinity Biotech is focused on addressing significant unmet clinical needs. The new partnership strengthens its capabilities in epigenetic analysis and reinforces its position as an innovator in the biotechnology sector, with the ultimate goal of improving patient health through smarter, less invasive diagnostics.

About Trinity Biotech

Trinity Biotech is a commercial stage biotechnology company focused on diabetes management solutions and human diagnostics, including wearable biosensors. The Company develops, acquires, manufactures and markets diagnostic systems, including both reagents and instrumentation, for the point-of-care and clinical laboratory segments of the diagnostic market and has recently entered the wearable biosensor industry, with the acquisition of the biosensor assets of Waveform Technologies Inc. and intends to develop a range of biosensor devices and related services, starting with a continuous glucose monitoring product. Their products are used to detect infectious diseases and to quantify the level of Haemoglobin A1c and other chemistry parameters in serum, plasma and whole blood. Trinity Biotech sells direct in the United States and through a network of international distributors and strategic partners in over 75 countries worldwide. For further information, please see the Company’s website: www.trinitybiotech.com.